$95.30
4.76% yesterday
Nasdaq, May 28, 10:00 pm CET
ISIN
US09627Y1091
Symbol
BPMC
Sector
Industry

Blueprint Medicines Corp. Stock price

$95.30
+6.79 7.67% 1M
+0.20 0.21% 6M
+8.08 9.26% YTD
-7.06 6.90% 1Y
+39.01 69.30% 3Y
+28.31 42.26% 5Y
+66.75 233.80% 10Y
Nasdaq, Closing price Wed, May 28 2025
-4.76 4.76%
ISIN
US09627Y1091
Symbol
BPMC
Sector
Industry

Key metrics

Market capitalization $6.46b
Enterprise Value $6.27b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 11.16
P/S ratio (TTM) P/S ratio 11.50
P/B ratio (TTM) P/B ratio 18.88
Revenue growth (TTM) Revenue growth 99.14%
Revenue (TTM) Revenue $562.12m
EBIT (operating result TTM) EBIT $-174.31m
Free Cash Flow (TTM) Free Cash Flow $-150.91m
Cash position $576.24m
EPS (TTM) EPS $-2.34
P/E forward negative
P/S forward 8.96
EV/Sales forward 8.70
Short interest 9.85%
Show more

Is Blueprint Medicines Corp. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,808 stocks worldwide.

Blueprint Medicines Corp. Stock Analysis

Unlock Scores for Free

Analyst Opinions

22 Analysts have issued a Blueprint Medicines Corp. forecast:

16x Buy
73%
5x Hold
23%
1x Sell
5%

Analyst Opinions

22 Analysts have issued a Blueprint Medicines Corp. forecast:

Buy
73%
Hold
23%
Sell
5%

Financial data from Blueprint Medicines Corp.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
562 562
99% 99%
100%
- Direct Costs 20 20
131% 131%
4%
542 542
98% 98%
96%
- Selling and Administrative Expenses 372 372
22% 22%
66%
- Research and Development Expense 345 345
15% 15%
61%
-158 -158
63% 63%
-28%
- Depreciation and Amortization 16 16
25% 25%
3%
EBIT (Operating Income) EBIT -174 -174
60% 60%
-31%
Net Profit -156 -156
46% 46%
-28%

In millions USD.

Don't miss a Thing! We will send you all news about Blueprint Medicines Corp. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Blueprint Medicines Corp. Stock News

Neutral
Business Wire
8 days ago
NEW YORK--(BUSINESS WIRE)-- #AI--VantAI, a leader in generative AI and proximity-based therapeutics, announced today that it has entered into a second expansion of its collaboration and license agreement with Blueprint Medicines, a global biopharmaceutical company, to prioritize targets and design and advance novel therapies for areas of high medical need. This new amendment further expands the...
Neutral
Seeking Alpha
27 days ago
Blueprint Medicines Corporation (NASDAQ:BPMC ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Jenna Cohen - Vice President, Investor Relations & Global Business Communications Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercial Officer Becker Hewes - Chief Medical Officer Mike Landsittel - Chief Financial Officer Christy Rossi - Chief Operating O...
Neutral
PRNewsWire
27 days ago
-- Achieved 61% year-over-year growth with $149.4 million in AYVAKIT net product revenues in the first quarter 2025 -- -- Raising AYVAKIT net product revenue guidance to $700 - $720 million for 2025 -- --  Initiated BLU-808 proof of concept studies in allergic rhinoconjunctivitis and chronic urticaria – CAMBRIDGE, Mass. , May 1, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC...
More Blueprint Medicines Corp. News

Company Profile

Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Head office United States
CEO Kathryn Haviland
Employees 649
Founded 2008
Website www.blueprintmedicines.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today